Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Heterogeneity of elderly depression: increased risk of Alzheimer's disease and Aβ protein metabolism.

Namekawa Y, Baba H, Maeshima H, Nakano Y, Satomura E, Takebayashi N, Nomoto H, Suzuki T, Arai H.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:203-8. doi: 10.1016/j.pnpbp.2012.12.016.

PMID:
23276885
2.

Metabolism of amyloid-β protein may be affected in depression.

Baba H, Nakano Y, Maeshima H, Satomura E, Kita Y, Suzuki T, Arai H.

J Clin Psychiatry. 2012 Jan;73(1):115-20. doi: 10.4088/JCP.10m06766.

PMID:
22152118
3.

Serum amyloid beta protein in young and elderly depression: a pilot study.

Kita Y, Baba H, Maeshima H, Nakano Y, Suzuki T, Arai H.

Psychogeriatrics. 2009 Dec;9(4):180-5. doi: 10.1111/j.1479-8301.2009.00293.x.

4.

Elevation of the Plasma Aβ40/Aβ42 Ratio as a Diagnostic Marker of Sporadic Early-Onset Alzheimer's Disease.

Kim HJ, Park KW, Kim TE, Im JY, Shin HS, Kim S, Lee DH, Ye BS, Kim JH, Kim EJ, Park KH, Han HJ, Jeong JH, Choi SH, Park SA.

J Alzheimers Dis. 2015;48(4):1043-50. doi: 10.3233/JAD-143018.

PMID:
26444752
5.

Depression and plasma amyloid beta peptides in the elderly with and without the apolipoprotein E4 allele.

Sun X, Chiu CC, Liebson E, Crivello NA, Wang L, Claunch J, Folstein M, Rosenberg I, Mwamburi DM, Peter I, Qiu WQ.

Alzheimer Dis Assoc Disord. 2009 Jul-Sep;23(3):238-44. doi: 10.1097/WAD.0b013e31819cb3ac.

6.

Plasma amyloid beta-42 independently predicts both late-onset depression and Alzheimer disease.

Blasko I, Kemmler G, Jungwirth S, Wichart I, Krampla W, Weissgram S, Jellinger K, Tragl KH, Fischer P.

Am J Geriatr Psychiatry. 2010 Nov;18(11):973-82. doi: 10.1097/JGP.0b013e3181df48be.

PMID:
20808106
7.

Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly.

Walker LC, Pahnke J, Madauss M, Vogelgesang S, Pahnke A, Herbst EW, Stausske D, Walther R, Kessler C, Warzok RW.

Acta Neuropathol. 2000 Jul;100(1):36-42.

PMID:
10912918
8.
9.

Heritability of plasma amyloid beta in typical late-onset Alzheimer's disease pedigrees.

Ertekin-Taner N, Graff-Radford N, Younkin LH, Eckman C, Adamson J, Schaid DJ, Blangero J, Hutton M, Younkin SG.

Genet Epidemiol. 2001 Jul;21(1):19-30.

PMID:
11443731
10.

The CC genotype of transforming growth factor-β1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression.

Caraci F, Bosco P, Signorelli M, Spada RS, Cosentino FI, Toscano G, Bonforte C, Muratore S, Prestianni G, Panerai S, Giambirtone MC, Gulotta E, Romano C, Salluzzo MG, Nicoletti F, Copani A, Drago F, Aguglia E, Ferri R.

Eur Neuropsychopharmacol. 2012 Apr;22(4):281-9. doi: 10.1016/j.euroneuro.2011.08.006.

PMID:
21924590
11.

Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

Mehta PD, Pirttilä T, Mehta SP, Sersen EA, Aisen PS, Wisniewski HM.

Arch Neurol. 2000 Jan;57(1):100-5.

PMID:
10634455
12.

Elevation in plasma Abeta42 in geriatric depression: a pilot study.

Pomara N, Doraiswamy PM, Willoughby LM, Roth AE, Mulsant BH, Sidtis JJ, Mehta PD, Reynolds CF 3rd, Pollock BG.

Neurochem Res. 2006 Mar;31(3):341-9.

PMID:
16583267
13.

Depression is associated with low plasma Abeta42 independently of cardiovascular disease in the homebound elderly.

Qiu WQ, Sun X, Selkoe DJ, Mwamburi DM, Huang T, Bhadela R, Bergethon P, Scott TM, Summergrad P, Wang L, Rosenberg I, Folstein M.

Int J Geriatr Psychiatry. 2007 Jun;22(6):536-42.

PMID:
17096467
14.

Genetic associations between cathepsin D exon 2 C-->T polymorphism and Alzheimer's disease, and pathological correlations with genotype.

Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Tian J, Shi J, Stopford C, Julien C, Thompson J, Payton A, Thaker U, Hayes AJ, Iwatsubo T, Pickering-Brown SM, Pendleton N, Horan MA, Burns A, Purandare N, Lendon CL, Neary D, Snowden JS, Mann DM.

J Neurol Neurosurg Psychiatry. 2006 Apr;77(4):515-7.

15.

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J.

Am J Pathol. 1999 Sep;155(3):853-62.

16.

Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease.

Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG.

Arch Neurol. 2007 Mar;64(3):354-62. Erratum in: Arch Neurol. 2007 Sep;64(9):1246.

PMID:
17353377
18.

Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide.

Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT.

J Neurosci. 2012 Oct 24;32(43):15181-92. doi: 10.1523/JNEUROSCI.1542-12.2012.

19.

Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment.

Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K.

Dement Geriatr Cogn Disord. 2007;23(5):316-20.

PMID:
17374949
20.

Plasma levels of Abeta42 and Abeta40 in Alzheimer patients during treatment with the acetylcholinesterase inhibitor tacrine.

Basun H, Nilsberth C, Eckman C, Lannfelt L, Younkin S.

Dement Geriatr Cogn Disord. 2002;14(3):156-60.

PMID:
12218259
Items per page

Supplemental Content

Support Center